T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55.
We assessed T-cell responses in young osteosarcoma patients vaccinated with 105AD7, 1-6 months after having received chemotherapy. 105AD7 is a human anti-idiotypic antibody mimicking CD55, a glycoprotein that protects from attack by complement and which is overexpressed on osteosarcoma cells. Seven out of 21 investigated patients made a IFN-gamma T-cell response against the vaccine, 105AD7 as assessed by ELISPOT. Cytokine secretion was analysed using Luminex assays and revealed TNF-alpha and GM-CSF responses not only to the vaccine but also towards the native antigen, CD55, in 5 / 14 (36%) of investigated patients. Importantly, the Luminex assay was found to be more sensitive than the more established T-cell assays (ELISPOT and proliferation assay), since responses towards the native antigen were recorded in this assay. Clinical responses and induction of immune responses to both the anti-idiotype and the native CD55 antigen support the use of CD55 as a target in cancer treatment.
Academic Department of Clinical Oncology, Nottingham City Hospital, Nottingham, NG5 1PB, UK. Gustav.Ullenhag@onkologi.uu.se
G J
GJ
Ullenhag
I
I
Spendlove
N F S
NF
Watson
C
C
Kallmeyer
K
K
Pritchard-Jones
L G
LG
Durrant
D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology; D001859:Bone Neoplasms / Q000276:immunology*; D018958:CD55 Antigens / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology*; D049109:Cell Proliferation; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000096:biosynthesis / Q000276:immunology; D006801:Humans; D007116:Immunization, Passive; D007124:Immunoenzyme Techniques; D007273:Injections, Intramuscular; D007279:Injections, Subcutaneous; D007371:Interferon-gamma / Q000096:biosynthesis / Q000276:immunology; D012516:Osteosarcoma / Q000276:immunology*; D037182:T-Cell Antigen Receptor Specificity; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000276:immunology; D006113:United Kingdom
C405618:105AD7 antibody; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D018958:CD55 Antigens; D019496:Cancer Vaccines; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma; D016178:Granulocyte-Macrophage Colony-Stimulating Factor